

# MY TOP 5 TAKES ON A PAPER TITLED

Comparative Effectiveness of Switching to Daptomycin (DAP) Versus Remaining on Vancomycin (VANC) Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)

1

## VANC = KING

VANC is commonly used for MRSA BSI. However, DAP is increasingly used for this as definitive therapy, especially when:

- 1) VANC has failed
- 2) MIC to VANC is increased (i.e.  $\geq 2$  mg/L)
- 3) Patient develops intolerance/side effects to VANC.

## STUDY DESIGN

2

Patients with MRSA BSI and treated with VANC were recruited retrospectively for 8 years (Jan 07 till Dec 14) from 124 VA hospitals. Intervention arm comprised of patients who were switched to DAP.

3

## 1.5% ONLY

7411 patients with MRSA BSI treated with VANC were included. Of these, 80% were switched to DAP at any time (median of 6 days, IQR 3-10 days) during their first hospitalization and 108 (1.5%) were switched within 3 days to DAP.

## EARLY ONLY

4

Patients who underwent early switch to DAP (within 3 days) were more likely to survive (day 30) vs. those who remained on VANC (HR 0.48; 95% confidence interval [CI]: 0.25- 0.92).

## TAKE HOME MSG



The therapeutic benefit of daptomycin in treating MRSA BSI might be **time dependent** as suggested by the study